Samsung Bio "Contract Manufacturing Competitiveness... Expanding Orders from Global Major Pharmaceutical Companies"

World's Largest Bio Conference
Held for Three Days in Italy
Larger Solo Booth than Before
Competitiveness Highlighted with Four Themes

The exclusive booth of Samsung Biologics set up at the world's largest biopharmaceutical conference, 'CPhI Worldwide 2021'.

[Milan, Italy = Asia Economy Reporter Seo So-jung] Samsung Biologics is accelerating its efforts to secure orders from global major pharmaceutical companies. The company, which is expanding its facilities to produce messenger ribonucleic acid (mRNA) active pharmaceutical ingredients with the goal of operation in the first half of next year, plans to enhance the status of K-bio by producing various forms of pharmaceuticals, including cell and gene therapies as well as COVID-19 vaccines, at a faster pace than competitors.

On the 9th (local time), Samsung Biologics will participate in 'CPhI Worldwide 2021,' the world's largest biopharmaceutical conference held in Milan, Italy, to actively promote its contract development and manufacturing organization (CDMO) competitiveness.

This event is the world's largest to be held simultaneously online and offline for the first time since COVID-19, running for three days from the 9th to the 11th. This year, about 1,400 companies from 170 countries worldwide are participating. Except for last year's event, which was held online due to COVID-19, Samsung Biologics has participated every year since 2018 with a dedicated booth. This year, it has prepared a dedicated booth of 260㎡, much larger than the 81㎡ booth in 2019.

Under the theme of 'Infinite Possibilities Toward the Future,' Samsung Biologics offers various content and events and conducts business networking. Inside the booth, a large panoramic panel showcasing the company's innovations and achievements at a glance is installed, highlighting the competitiveness of its CDMO business through four themes.

First, it emphasizes the competitiveness of Plant 4, the world's largest single-factory production facility with a capacity of 256,000 liters. Plant 4 is a super plant equipped with state-of-the-art equipment and optimized processes, enabling all processes from cell line development to commercial production in one location. Once Plant 4 begins operation, Samsung Biologics will secure a total production capacity of 620,000 liters.

Samsung Biologics also introduces 'S-Cellerate,' an accelerated contract development platform to its clients. S-Cellerate is a service that optimizes and supports each process from early development stages to Investigational New Drug (IND) application, and from late development stages to Biologics License Application (BLA). Through this, clients can reduce the time required to develop biopharmaceuticals by up to nine months.

Additionally, it seeks differentiation through business portfolio diversification via multimodality. Multimodality refers to producing various forms of pharmaceuticals such as cell and gene therapies and vaccines in a single factory. Samsung Biologics is expanding its facilities to produce mRNA active pharmaceutical ingredients, aiming for operation in the first half of next year.

It also actively promotes its 'end-to-end service,' which can provide one-stop solutions from early-stage biopharmaceutical development to commercial production. A Samsung Biologics official said, "Last year, we opened a contract development (CDO) research and development (R&D) center in San Francisco, USA, strengthening our global contract development order capabilities," adding, "We plan to further expand CMO production capacity by establishing a second bio campus in Songdo, Incheon in the future."

This content was produced with the assistance of AI translation services.